Boosting CAR t: early second dose may keep childhood leukemia at bay

NCT ID NCT05460533

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a second dose of the CAR T-cell therapy tisagenlecleucel early can keep the immune system's B cells low for at least 6 months in children and young adults with relapsed B-cell acute lymphoblastic leukemia. The goal is to reduce the chance of the cancer coming back. The trial involves 30 participants who already received their first dose and have extra doses available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia Burkitt lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Children's Hospital Colorado (Data Collection Only)

Aurora, Colorado, 80045, United States
Children's Hospital of Los Angeles (Data Collection Only)

Los Angeles, California, 90027, United States
Cincinnati Children's Hospital Medical Center (Data Collection Only)

Cincinnati, Ohio, 45229, United States
Johns Hopkins University (Data Collection Only)

Baltimore, Maryland, 21287, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Stanford University (Data Collection Only)

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.